An excellent article in which the authors exerted a great and wonderful effort and discussed an extremely important topic for HCP, patients and health in general: I have only two comments which will strengthen the article: Please add to your text example for low income countries and add several challenges that face running strong pharmacovigilance activities in developing countries. What are the strategies to uplift the current PV program in UAE and developing countries? Strategies such as teaching PV and enhancing patients and consumer reporting etc... 